523 related articles for article (PubMed ID: 30517603)
41. Effectiveness of palivizumab immunoprophylaxis in infants with respiratory syncytial virus disease in Colombia.
Piñeros JG; De la Hoz-Valle J; Galvis C; Celis A; Ovalle O; Sandoval CC; Orrego J; Vides S; Rojas I; Bustamante H; Gallón C; Mesa JA
J Infect Dev Ctries; 2021 Nov; 15(11):1708-1713. PubMed ID: 34898500
[TBL] [Abstract][Full Text] [Related]
42. Impact of the 2014 American Academy of Pediatrics recommendation and of the resulting limited financial coverage by the Italian Medicines Agency for palivizumab prophylaxis on the RSV-associated hospitalizations in preterm infants during the 2016-2017 epidemic season: a systematic review of seven Italian reports.
Cutrera R; Wolfler A; Picone S; Rossi GA; Gualberti G; Merolla R; Del Vecchio A; Villani A; Midulla F; Dotta A
Ital J Pediatr; 2019 Nov; 45(1):139. PubMed ID: 31706338
[TBL] [Abstract][Full Text] [Related]
43. Risk of RSV-related hospitalization is associated with gestational age in preterm (born at 29-34 wGA) infants without outpatient palivizumab administration.
Packnett ER; Winer IH; Oladapo A; Wojdyla M
Hum Vaccin Immunother; 2023 Aug; 19(2):2252289. PubMed ID: 37828711
[TBL] [Abstract][Full Text] [Related]
44. Impact of the 2014 American Academy of Pediatrics Immunoprophylaxis Policy on the Rate, Severity, and Cost of Respiratory Syncytial Virus Hospitalizations among Preterm Infants.
Krilov LR; Fergie J; Goldstein M; Brannman L
Am J Perinatol; 2020 Jan; 37(2):174-183. PubMed ID: 31430818
[TBL] [Abstract][Full Text] [Related]
45. Beyond randomized controlled trials: a "real life" experience of respiratory syncytial virus infection prevention in infancy with and without palivizumab.
Mitchell I; Tough S; Gillis L; Majaesic C
Pediatr Pulmonol; 2006 Dec; 41(12):1167-74. PubMed ID: 17058279
[TBL] [Abstract][Full Text] [Related]
46. Evaluation of recent New Vaccine Surveillance Network data regarding respiratory syncytial virus hospitalization rates in US preterm infants.
DeVincenzo JP; Ambrose CS; Makari D; Weiner LB
Hum Vaccin Immunother; 2016 Apr; 12(4):971-5. PubMed ID: 26889568
[TBL] [Abstract][Full Text] [Related]
47. Risk-Scoring Tool for respiratory syncytial virus prophylaxis in premature infants born at 33-35 completed weeks' gestational age in Canada.
Paes B; Steele S; Janes M; Pinelli J
Curr Med Res Opin; 2009 Jul; 25(7):1585-91. PubMed ID: 19469698
[TBL] [Abstract][Full Text] [Related]
48. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.
Pediatrics; 1998 Sep; 102(3 Pt 1):531-7. PubMed ID: 9738173
[TBL] [Abstract][Full Text] [Related]
49. Serious Adverse Events in the Canadian Registry of Children Receiving Palivizumab (CARESS) for Respiratory Syncytial Virus Prevention.
Chen JJ; Chan P; Paes B; Mitchell I; Li A; Lanctôt KL;
PLoS One; 2015; 10(8):e0134711. PubMed ID: 26237402
[TBL] [Abstract][Full Text] [Related]
50. The increasing age of respiratory syncytial virus-related hospitalisation during COVID-19 pandemic in Lyon was associated with reduced hospitalisation costs.
Roy Á; Polazzi S; Ploin D; Gillet Y; Javouhey E; Lina B; ; Myard-Dury AF; Couray-Targe S; Duclos A; Casalegno JS
Vaccine; 2023 Jun; 41(25):3796-3800. PubMed ID: 37198017
[TBL] [Abstract][Full Text] [Related]
51. Update on respiratory syncytial virus hospitalizations among U.S. preterm and term infants before and after the 2014 American Academy of Pediatrics policy on immunoprophylaxis: 2011-2017.
Fergie J; Goldstein M; Krilov LR; Wade SW; Kong AM; Brannman L
Hum Vaccin Immunother; 2021 May; 17(5):1536-1545. PubMed ID: 33090914
[TBL] [Abstract][Full Text] [Related]
52. Product review on the monoclonal antibody palivizumab for prevention of respiratory syncytial virus infection.
Resch B
Hum Vaccin Immunother; 2017 Sep; 13(9):2138-2149. PubMed ID: 28605249
[TBL] [Abstract][Full Text] [Related]
53. Cost-utility analysis of Palivizumab for Respiratory Syncytial Virus infection prophylaxis in preterm infants: update based on the clinical evidence in Spain.
Sanchez-Luna M; Burgos-Pol R; Oyagüez I; Figueras-Aloy J; Sánchez-Solís M; Martinón-Torres F; Carbonell-Estrany X
BMC Infect Dis; 2017 Oct; 17(1):687. PubMed ID: 29041909
[TBL] [Abstract][Full Text] [Related]
54. A population-weighted, condition-adjusted estimate of palivizumab efficacy in preventing RSV-related hospitalizations among US high-risk children.
Ambrose CS; Chen X; Kumar VR
Hum Vaccin Immunother; 2014; 10(10):2785-8. PubMed ID: 25483483
[TBL] [Abstract][Full Text] [Related]
55. Respiratory syncytial virus prophylaxis in Down syndrome: a prospective cohort study.
Yi H; Lanctôt KL; Bont L; Bloemers BL; Weijerman M; Broers C; Li A; Kiss A; Mitchell I; Paes B;
Pediatrics; 2014 Jun; 133(6):1031-7. PubMed ID: 24799541
[TBL] [Abstract][Full Text] [Related]
56. Mortality and morbidity among infants at high risk for severe respiratory syncytial virus infection receiving prophylaxis with palivizumab: a systematic literature review and meta-analysis.
Checchia PA; Nalysnyk L; Fernandes AW; Mahadevia PJ; Xu Y; Fahrbach K; Welliver RC
Pediatr Crit Care Med; 2011 Sep; 12(5):580-8. PubMed ID: 21200358
[TBL] [Abstract][Full Text] [Related]
57. Six-monthly palivizumab prophylaxis effectively reduced RSV-associated hospitalization rates of preterm infants in a subtropical area: a population-based cohort study.
Lin YJ; Chung CH; Chi H; Lin CH
Pediatr Res; 2019 Nov; 86(5):628-634. PubMed ID: 31261371
[TBL] [Abstract][Full Text] [Related]
58. Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children.
Andabaka T; Nickerson JW; Rojas-Reyes MX; Rueda JD; Bacic Vrca V; Barsic B
Cochrane Database Syst Rev; 2013 Apr; (4):CD006602. PubMed ID: 23633336
[TBL] [Abstract][Full Text] [Related]
59. Palivizumab prophylaxis for respiratory syncytial virus in Canada: utilization and outcomes.
Oh PI; Lanctôt KL; Yoon A; Lee DS; Paes BA; Simmons BS; Parison D; Manzi P;
Pediatr Infect Dis J; 2002 Jun; 21(6):512-8. PubMed ID: 12182374
[TBL] [Abstract][Full Text] [Related]
60. Efficacy and long-term outcomes of palivizumab prophylaxis to prevent respiratory syncytial virus infection in infants with cystic fibrosis in Northern Ireland.
Groves HE; Jenkins L; Macfarlane M; Reid A; Lynn F; Shields MD
Pediatr Pulmonol; 2016 Apr; 51(4):379-85. PubMed ID: 26808981
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
